Large effect sizes seen for Beck Depression Inventory, Recovery Assessment Scale, Rosenberg Self-Esteem Scale<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Nov. 22, 2021 (HealthDay News) — For patients with severe mental illness (SMI), a smartphone intervention is highly usable and acceptable and improves outcomes, according to a study published online Nov. 12 in the Journal of Medical Internet Research<\/em>.<\/p>\n Dror Ben-Zeev, Ph.D., from the University of Washington in Seattle, and colleagues conducted a trial of CORE, a smartphone intervention that includes daily exercises designed to promote reassessment of dysfunctional beliefs. A total of 315 individuals from 45 states were randomly assigned to either active intervention or wait-list control groups. Participants were assessed at baseline, 30 days, and 60 days with the Beck Depression Inventory-Second Edition (BDI-II), Generalized Anxiety Disorder-7 (GAD-7), Hamilton Program for Schizophrenia Voices, Green Paranoid Thought Scale, Recovery Assessment Scale (RAS), Rosenberg Self-Esteem Scale (RSES), Friendship Scale, and Sheehan Disability Scale (SDS).<\/p>\n Participants had self-reported bipolar disorder, major depressive disorder, and schizophrenia or schizoaffective disorder (35.2, 43.2, and 21.6 percent, respectively) and displayed moderate-to-severe symptoms and disability levels at baseline. The researchers found that CORE was rated as acceptable and highly usable. Significant treatment-by-time interactions were seen for the BDI-II, GAD-7, RAS, RSES, and SDS in intent-to-treat analyses. Large effect sizes were seen for the BDI-II, RAS, and RSES, while the SDS had a moderate effect size and a small effect size was seen for GAD-7. Following cross-over of wait-list controls to CORE, similar changes in outcome measures were observed.<\/p>\n “New scientific evidence showing that remotely-accessed mobile health technologies such as CORE can be navigable and beneficial to people with SMI is very encouraging,” the authors write.<\/p>\n One author disclosed financial ties to pharmaceutical and technology industries.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n